SUMMARY
min in the control, neostigmine and edrophonium groups, respectively. The durations TOF W in the neostigmine (P < 0.01) and edrophonium (P < 0.01), groups were shorter than control. The duration TOF 10 of the neostigmine group was shorter than in the edrophonium group (P < 0.01). These results show that profound neuromuscular blockade cannot be rapidly antagonized by either of these two agents, but if reversal is required under these circumstances, neostigmine would be the more effective drug.
PATIENTS AND METHODS
Fifty-nine healthy patients gave informed consent to their inclusion in this study, which was approved by the Ethics Committee. Approximately by guest on November 4, 2016 http://bja.oxfordjournals.org/ Downloaded from 1 h after premedication with papaveretum 10-20 mg plus hyoscine 0.2-0.4 mg i.m., anaesthesia was induced with thiopentone 4-5 mg kg" 1 i.v. and was maintained thereafter with 67 % nitrous oxide in oxygen plus 1 % halothane (inspired). The Myograph 2000 neuromuscular transmission analyser (Biometer, Denmark) was used to deliver supramaximal stimuli of 0.2 ms duration at a frequencey of 0.1 Hz to the ulnar nerve via subcutaneous needle electrodes placed at the wrist, and to transduce and record the resulting evoked responses of the adductor pollicis muscle. Before the administration of the neuromuscular blocking drug, control responses to single twitch (0.1 Hz) and train-of-four (TOF) stimulation were recorded for at least 10 min, to allow stabilization.
The first 30 patients received vecuronium 0.1 mg kg" 1 i.v. Tracheal intubation was performed when 100% depression of twitch height was achieved, and IPPV was instituted. Five minutes after total ablation of the single twitch response, the patients were allocated randomly to one of three groups: group 1 (control) received no antagonist; group 2 received neostigmine 0.07 mg kg" 1 plus atropine 1.2 mg i.v.; group 3 received edrophonium 0.8 mg kg" 1 plus atropine 1.2 mg i.v. When twitch height had returned to control the stimulation mode was changed to TOF and monitoring was continued until the TOF ratio was 70%.
All times were measured from the end of injection of the neuromuscular blocking drug. Indices recorded were: onset (time to 100% Subsequently, a further 29 patients were studied; neuromuscular blockade was induced with atracurium 0.5 mg kg" 1 i.v. and an identical programme of study used.
Statistical analysis was by unpaired Student's r test. P < 0.05 was considered significant.
RESULTS
Physical characteristics of the patients are detailed in table I. The control patients who received vecuronium were younger than those in the neostigmine and edrophonium groups. Otherwise, the groups were comparable. There was no difference between the groups in the onset of neuromuscular blockade. Taking all the vecuronium patients, the mean onset time was 2.4 min (range 1.5-4.4 min). The equivalent time for the atracurium group was 2.4 min (1.3-5.9 min).
The indices of recovery in the patients who received vecuronium are shown in table II. The durations 5, 25, 95 and TOF 70 were shorter in the neostigmine group than in the edrophonium and control groups.The duration 5 of the edrophonium group was shorter than that in the control group.
The indices of recovery in the patients who received atracurium are shown in table III. The durations 5, 25, 95 and TOF 70 were shorter in the neostigmine group than in the edrophonium and control groups. The durations 5, 25, 95 and TOF 70 were shorter in the edrophonium group than in the control group. were no differences between the groups in recovery index (time from 25% to 75% twitch height recovery).
DISCUSSION
In this study with halothane used to maintain anaesthesia, the mean durations TOF 70 of the control groups, after intubating doses of vecuronium O.lmgkg" 1 and atracurium 0.5 mg kg" 1 , were 66.7 and 66.4 min, respectively. This suggests that, in these circumstances, it is probably necessary to antagonize residual neuromuscular blockade for up to 1 h after the injection of these doses of vecuronium and atracurium. The onset times for vecuronium and atracurium in this study were in agreement with previous reports (Gramstad, Lilleaasen and Minsaas, 1982; Robertson et al., 1983) .
The effect of age on the potency of vecuronium was studied by d'Hollander and colleagues (1982) . Patients aged younger than 40 yr were compared with patients aged between 40 and 60 yr and no difference in potency was demonstrated. It seems reasonable to conclude, therefore, that the age difference within the vecuronium group was not an important factor in the interpretation of our results.
Since the doses of neostigmine and edrophonium were equipotent (Cronnelly, Morris and Miller, 1982; Baird, Bowman and Kerr, 1982) , the groups can be compared with each other. In this study, neostigmine reduced the duration of action of vecuronium and atracurium compared with control. In contrast, edrophonium had no effect on the duration of action of vecuronium, but it did reduce the duration of action of atracurium. Edrophonium was less effective than neostigmine against either of these neuromuscular blocking agents. Since edrophonium has been shown to have a faster onset of action than neostigmine (Morris et al., 1981) , it might have been expected that the duration 5, being the first clear evidence of a returning twitch response, would have been shorter in the edrophonium group. In fact, mean duration 5 was shorter in patients receiving either vecuronium or atracurium after neostigmine ( fig. 1) .
When antagonizing stable 90% tubocurarineinduced neuromuscular blockade, the time to the peak effect of edrophonium was 0.8-2.0 min (Cronnelly, Morris and Miller, 1982) , and to peak effect of neostigmine was 7-11 min (Miller et al., 1974) . In the present study, the concentrations of vecuronium and atracurium at the neuromuscular junction, when the antagonists were exerting their peak effect, were unknown. The more rapid demonstrable effect of neostigmine, in this study, was perhaps simply the result of a greater degree of spontaneous recovery being present when the neostigmine has its peak effect.
It has been suggested that the administration of an anticholinesterase, when there is likely to be a high concentration of vecuronium or atracurium at the neuromuscular junction, might induce some degree of ion-channel occlusion and that blockade would be enhanced (Bowman, 1985) . No evidence of such an effect was found in this study: compared with control, the duration of neuromuscular blockade was not prolonged following the administration of neostigmine or edrophonium. However, it is not possible to dismiss the possibility of ion-channel occlusion, since this might explain why neither anticholinesterase agent induced a rapid, satisfactory antagonism of neuromuscular blockade.
After the twitch height reached 25 % of control, the rate of recovery was similar in all groups ( fig.  1) . Differences in the durations 95 and TOF 70 merely reflected events in the early phase of recovery and were probably not the result of a continuing process of antagonism. Therefore, the effectiveness of neostigmine and edrophonium as antagonizing agents would appear to be more dependent on their initial effect than on their duration of action.
Recently, Rupp, McChristian and Miller (1984) investigated the antagonism of vecuronium-, pancuronium-and atracurium-induced neuromuscular blockade by neostigmine or edrophonium, administered when the twitch height was less than 10% of the control response. Their results demonstrated that both antagonists were equally effective against atracurium, but that edrophonium was less effective than neostigmine against vecuronium and pancuronium. Although, in the present study, edrophonium was less effective than neostigmine in antagonizing atracurium-induced blockade, the results of these other workers are generally confirmed. Vecuronium has a predominantly postjunctional action (Bowman, Gibb and Marshall, 1983) , while edrophonium has a significant prejunctional effect (Blaber, 1972) , which is proportionately greater than that of neostigmine (Donati, Ferguson and Bevan, 1983) . Under the conditions of the present and previous studies (Rupp, McChristian and Miller, 1984) , the mode of action of edrophonium may be poorly matched to the neuromuscularblocking properties of vecuronium and this might account for the relative ineffectiveness of edrophonium against vecuronium.
Neither neostigmine nor edrophonium will rapidly antagonize profound neuromuscular blockade induced by vecuronium or atracurium. In the clinical situation, antagonism of profound blockade is sometimes attempted either deliberately, for example after failed tracheal intubation, or unwittingly when neuromuscular function is not monitored. However, of the two drugs, neostigmine appears to be the more effective if antagonism of profound neuromuscular blockade is to be attempted.
